Earnings Feed
Start Free
Akero Therapeutics, Inc.·4

Nov 6, 7:00 AM ET

Yale Catriona 4

4 · Akero Therapeutics, Inc. · Filed Nov 6, 2025

Insider Transaction Report

Form 4
Period: 2025-11-04
Akero Therapeutics, Inc.AKRO
Yale Catriona
Chief Development Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-11-04$28.35/sh+3,527$99,990→ 70,061 total
  • Exercise/Conversion

    Common Stock

    2025-11-04$21.10/sh+4,739$99,993→ 74,800 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-04−4,739→ 0 total
    Exercise: $21.10Exp: 2031-12-07→ Common Stock (4,739 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-04−3,527→ 0 total
    Exercise: $28.35Exp: 2030-12-07→ Common Stock (3,527 underlying)
Footnotes (2)
  • [F1]The reported amount has been adjusted to correct for an overstatement in the Reporting Person's previously reported common stock ownership.
  • [F2]The options are vested and currently exercisable.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4